EA201890816A1 - Вариант 7as андрогенового рецептора как биомаркер для выбора лечения пациентов с метастатическим раком простаты, резистентным к кастрации (mcrpc) - Google Patents

Вариант 7as андрогенового рецептора как биомаркер для выбора лечения пациентов с метастатическим раком простаты, резистентным к кастрации (mcrpc)

Info

Publication number
EA201890816A1
EA201890816A1 EA201890816A EA201890816A EA201890816A1 EA 201890816 A1 EA201890816 A1 EA 201890816A1 EA 201890816 A EA201890816 A EA 201890816A EA 201890816 A EA201890816 A EA 201890816A EA 201890816 A1 EA201890816 A1 EA 201890816A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mcrpc
castration
prostate cancer
metastatic prostate
patients
Prior art date
Application number
EA201890816A
Other languages
English (en)
Inventor
Райан Диттамор
Original Assignee
Эпик Сайенсиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эпик Сайенсиз, Инк. filed Critical Эпик Сайенсиз, Инк.
Publication of EA201890816A1 publication Critical patent/EA201890816A1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Данное изобретение предоставляет способ идентификации пациентов, страдающих метастатическим раком простаты, резистентным к кастрации (mCRPC), с усиленным ответом на терапию таксаном по сравнению с терапией, направленной на андрогеновый рецептор (AR), содержащий (a) выполнение прямого анализа, содержащего иммунофлуоресцентное окрашивание и морфологическую характеризацию клеток, содержащих ядро, в образце крови, полученном для генерации данных о циркулирующих в крови опухолевых клетках (CTC), причем анализ содержит детектирование наличия варианта 7 андрогенового рецептора (AR-V7) в упомянутых клетках, и (c) оценку данных о CTC для идентификации пациентов с mCRPC с усиленным ответом на терапию таксаном по сравнению с терапией, направленной на ARS.
EA201890816A 2015-09-25 2016-09-23 Вариант 7as андрогенового рецептора как биомаркер для выбора лечения пациентов с метастатическим раком простаты, резистентным к кастрации (mcrpc) EA201890816A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562233206P 2015-09-25 2015-09-25
PCT/US2016/053387 WO2017053763A2 (en) 2015-09-25 2016-09-23 ANDROGEN RECEPTOR VARIANT 7 AS A BIOMARKER FOR TREATMENT SELECTION IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC)

Publications (1)

Publication Number Publication Date
EA201890816A1 true EA201890816A1 (ru) 2018-09-28

Family

ID=58387342

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890816A EA201890816A1 (ru) 2015-09-25 2016-09-23 Вариант 7as андрогенового рецептора как биомаркер для выбора лечения пациентов с метастатическим раком простаты, резистентным к кастрации (mcrpc)

Country Status (9)

Country Link
US (2) US20190285636A1 (ru)
EP (1) EP3353553B1 (ru)
JP (1) JP6936231B2 (ru)
CN (3) CN118443943A (ru)
AU (1) AU2016325617A1 (ru)
CA (1) CA2999911A1 (ru)
EA (1) EA201890816A1 (ru)
IL (1) IL258318A (ru)
WO (1) WO2017053763A2 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101926117B1 (ko) * 2017-08-18 2018-12-06 주식회사 싸이토젠 안드로겐 수용체의 변이체 기반 전립선암환자 스크리닝 방법
JP2022527505A (ja) * 2019-03-28 2022-06-02 カーディフ・オンコロジー・インコーポレイテッド Ｐｌｋ１阻害薬及び前立腺癌のｐｓａレベル

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9671405B2 (en) * 2012-09-19 2017-06-06 Cornell University Identifying taxane sensitivity in prostate cancer patients
EA201691496A1 (ru) * 2014-01-27 2016-12-30 Эпик Сайенсиз, Инк. Диагностика биомаркеров рака предстательной железы с помощью циркулирующих опухолевых клеток
ES2868077T3 (es) * 2014-01-30 2021-10-21 Epic Sciences Inc Diagnóstico mediante células tumorales circulantes para biomarcadores predictivos de la resistencia a las terapias selectivas del receptor de andrógenos (RA)

Also Published As

Publication number Publication date
JP2018535432A (ja) 2018-11-29
CN118443943A (zh) 2024-08-06
CA2999911A1 (en) 2017-03-30
WO2017053763A2 (en) 2017-03-30
US20240036047A1 (en) 2024-02-01
IL258318A (en) 2018-05-31
WO2017053763A3 (en) 2017-12-21
JP6936231B2 (ja) 2021-09-15
CN108450001A (zh) 2018-08-24
EP3353553A2 (en) 2018-08-01
CN118443942A (zh) 2024-08-06
EP3353553A4 (en) 2019-04-17
EP3353553B1 (en) 2021-11-17
AU2016325617A1 (en) 2018-04-19
US20190285636A1 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
Criscitiello et al. Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer
EA201691505A1 (ru) Детектирование экспрессии простатического специфического мембранного антигена (psma) на циркулирующих опухолевых клетках (ctc)
MX2022006075A (es) Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer.
MX2020004567A (es) Metodos diagnosticos y terapeuticos para el cancer.
EA201691496A1 (ru) Диагностика биомаркеров рака предстательной железы с помощью циркулирующих опухолевых клеток
MX2018008421A (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
EA201891571A1 (ru) Геномное профилирование отдельных циркулирующих опухолевых клеток (ctc) при метастазирующем заболевании для характеризации гетерогенности заболевания
EA201792497A1 (ru) Антитела к gitr для диагностики злокачественной опухоли
EP3839510A3 (en) Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
EA201691352A1 (ru) Диагностика рака легкого с помощью циркулирующих опухолевых клеток
EA201891304A1 (ru) ИНГИБИТОРЫ MAT2A ДЛЯ ЛЕЧЕНИЯ MTAP-null ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ
EA201691499A1 (ru) Диагностика с помощью циркулирующих опухолевых клеток биомаркеров, позволяющих предсказывать резистентность по отношению к направленным на андрогеновый рецептор (ar) терапиям
EP4282405A3 (en) Detection of cancer biomarkers using nanoparticles
WO2015094995A3 (en) Gene signature biomarkers of tumor response to pd-1 antagonists
GB2545361A (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
WO2018183817A3 (en) Tumor burden as measured by cell free dna
BR112016018044A2 (pt) teste de diagnóstico molecular para prever resposta às drogas antiangiogênicas e prognóstico de câncer
TR201907389T4 (tr) Meme kanserinden kaynaklanan metastazlı kemik kanserinin prognozu ve tedavisine yönelik yöntem.
WO2018097614A3 (ko) 유방암 환자의 화학치료 유용성 예측 방법
WO2015094996A3 (en) Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
MX2016012697A (es) Perfiles de marcadores biologicos de proteina para detectar tumores colorrectales.
MX2018009254A (es) Metodos para evaluar el riesgo de desarrollar cancer colorrectal.
BR112016024143A2 (pt) tratamento de câncer
EA201691497A1 (ru) Способы детектирования и количественного определения имитаторов циркулирующих опухолевых клеток
EA201891085A1 (ru) Получение геномных профилей отдельных клеток для циркулирующих клеток опухолей (ctc) при метастазирующем заболевании для характеризации гетерогенности заболевания